New findings published in Diabetes Care highlight meaningful differences in cardiovascular outcomes among commonly prescribed diabetes therapies. Researchers found that tirzepatide—marketed as Mounjaro—was associated with a lower risk of major cardiovascular events compared to dulaglutide (Trulicity) in adults with type 2 diabetes and existing cardiovascular disease.
The study analyzed real-world data from a large national database, comparing outcomes across multiple GLP-1–based therapies. While tirzepatide demonstrated a reduced rate of cardiovascular events versus dulaglutide, researchers found no significant difference in cardiovascular risk when compared to semaglutide (Ozempic).
For providers, these findings offer additional insight into treatment selection for patients with both type 2 diabetes and cardiovascular disease, reinforcing the importance of tailoring therapy based on individual risk profiles and clinical goals.
Resource: Tirzepatide linked to lower CV risk than dulaglutide for adults with type 2 diabetes